Revenue
2024
2025
| 2025 | 2024 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | — | — |
| Operating expenses | $153,903 | $250,229 | $672,162 | $18,911 | $1.2M | $757,935 | $2.1M |
| Operating income | −$153,903 | −$250,229 | −$672,162 | −$18,911 | −$1.2M | −$757,935 | −$2.1M |
| EBITDA | −$147,594 | −$243,831 | — | — | — | −$757,935 | −$2.0M |
| Net income | −$155,907 | −$250,229 | −$672,162 | −$18,911 | −$1.0M | $3.7M | −$1.1M |
| Basic EPSper basic share | $0.00 | $0.00 | -$0.04 | $0.10 | -$1.10 | $4.20 | -$1.30 |
| Diluted EPSper diluted share | $0.00 | $0.00 | -$0.04 | $0.10 | -$1.10 | $4.00 | -$1.30 |
Reported shareholders
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 17, 2025Form 4 | CTT PHARMACEUTICAL HOLDINGS, INC.CEO | BuyCTTH | 8.3K | $0.06 | $498.00 | 7.85M |
| Nov 20, 2025Form 4 | CTT PHARMACEUTICAL HOLDINGS, INC.Director | BuyCTTH | 200.0K | $0.04 | $8.0K | 3.73M |
| Nov 20, 2025Form 4 | CTT PHARMACEUTICAL HOLDINGS, INC.CEO | BuyCTTH | 62.9K | $0.04 | $2.5K | 7.84M |
| Oct 31, 2025Form 4 | CTT PHARMACEUTICAL HOLDINGS, INC.CEO | BuyCTTH | 7.0K | $0.06 | $420.00 | 7.77M |
| Sep 23, 2025Form 4 | CTT PHARMACEUTICAL HOLDINGS, INC.CEO | BuyCTTH | 6.8K | $0.06 | $408.90 | 7.77M |